Description
CJC-1295 (No DAC) / Ipamorelin is a dual-peptide research blend combining two distinct synthetic compounds: a growth hormone-releasing hormone (GHRH) analogue and a selective ghrelin receptor agonist (growth hormone secretagogue). CJC-1295 without DAC is a modified 29-amino-acid peptide that mirrors the active fragment of endogenous GHRH, while Ipamorelin is a pentapeptide that engages the ghrelin/GHS-R1a receptor pathway independently. Together, they represent two complementary but mechanistically separate inputs into somatotroph signaling.
Because the two peptides operate through non-overlapping receptor classes, investigators use this blend to probe the additive or synergistic dynamics of pulsatile growth hormone (GH) release in controlled experimental systems. The absence of a Drug Affinity Complex (DAC) on the CJC-1295 component means the compound does not bind albumin for extended half-life, making it suitable for study designs that require discrete, time-resolved signaling pulses rather than continuous receptor activation.
The formulation is prepared under controlled manufacturing conditions and is characterized as a lyophilized, high-purity, endotoxin-tested blend. Low endotoxin content is a critical quality attribute for cellular and biochemical assay work, where lipopolysaccharide contamination can independently activate inflammatory pathways and confound experimental readouts. Batch-level endotoxin screening supports reproducibility across sensitive in vitro models.
